Immunohistochemical Evaluation of Cathepsin B, L, and S Expression in Breast Cancer Patients
The expression of at least one of the cysteine cathepsins B, L and S in all breast tumor tissues tested suggests that cathepsin-activatable imaging agents with broad reactivity for these three proteases will likely be effective in the vast majority of breast cancer patients, regardless of molecular subtype and treatment status. Patients with high grade ER-negative, HER2-positive, or TN tumors might show higher imaging signals.
Authors
- Matthew S. Bogyo (ORCID: https://orcid.org/0000-0003-3753-4412)
- Daan G. J. Linders (ORCID: https://orcid.org/0000-0003-4524-4175)
- Laura C. Fallert
- Taryn L. March
- Martin Pool (ORCID: https://orcid.org/0000-0002-4892-3109)
- Denise E. Hilling (ORCID: https://orcid.org/0000-0002-5875-6164)
- Ethan Walker (ORCID: https://orcid.org/0000-0002-5132-8191)
- Okker D. Bijlstra (ORCID: https://orcid.org/0000-0001-9069-500X)
- Peter J.K. Kuppen (ORCID: https://orcid.org/0000-0002-0294-3251)
- N. Geeske Dekker-Ensink
- Brian Straight
- James P. Basilion (ORCID: https://orcid.org/0000-0002-8659-3307)
- Jacobus Burggraaf (ORCID: https://orcid.org/0000-0001-7912-0918)
- Alexander L Vahrmeijer
- A. Stijn L. P. Crobach
Institutions
- Leiden University (NL)
- Leiden University Medical Center (NL)
- Akrotome Imaging (United States) (US)
- Centre for Human Drug Research (NL)
- Erasmus MC Cancer Institute (NL)
- Case Western Reserve University (US)
- Stanford University (US)
Publication Details
- Journal
- Molecular Imaging and Biology
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1007/s11307-024-01955-5
- Citations
- 8
- Primary Topic
- Bone and Dental Protein Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.76
Funders
- Foundation for the National Institutes of Health